Today: 23 January 2026
Subscribe
Browse Category

NYSE:BTI News 15 January 2026 - 23 January 2026

British American Tobacco share price in focus before London open after buyback disclosure

British American Tobacco share price in focus before London open after buyback disclosure

London, Jan 23, 2026, 07:59 GMT — Premarket British American Tobacco shares are set to draw attention on Friday following the announcement of another share buyback program, extending focus on capital returns after a solid previous session. (Sharecast) The London-listed tobacco firm has long been a reliable “income” play for investors, boasting a dividend yield north of 5% alongside a…
23 January 2026
·····
Philip Morris stock edges up after PMI flags $20B+ U.S. investment push, FDA ZYN review ahead

Philip Morris stock edges up after PMI flags $20B+ U.S. investment push, FDA ZYN review ahead

NEW YORK, Jan 15, 2026, 15:42 EST — Regular session. Philip Morris International Inc shares climbed Thursday after the company revealed it has poured over $20 billion into U.S.-related investments since 2022, with more spending on the horizon. The stock added $1.40, or roughly 0.8%, reaching $172.48 in afternoon trading. (Business Wire) The update arrives as investors seek signs that…
15 January 2026
······
BAT stock in focus: British American Tobacco buyback update hits ahead of February results

BAT stock in focus: British American Tobacco buyback update hits ahead of February results

London, Jan 15, 2026, 07:37 GMT — Premarket British American Tobacco said it bought back 118,229 shares on Jan. 14 at prices between 4,160p and 4,245p, paying a volume-weighted average price (VWAP, a volume-weighted trading price) of 4,197.4176p. It said it would cancel the shares, taking the number of voting shares in issue to 2,178,299,552, excluding treasury stock. (Investegate) The…
15 January 2026
······

Stock Market Today

  • CMP.AX stock jumps 38.46% to A$0.45 on ASX amid volume surge
    January 23, 2026, 7:20 AM EST. CMP.AX led ASX gainers on January 23, closing at A$0.45, up 38.46% on heavy volume of 695,750 shares, nearly nine times average. The rise broke through the 50-day average price of A$0.35. Drivers include improved quarterly flows and stronger demand for sleep and neurology diagnostic equipment. Financials show modest liquidity with ongoing profit challenges; EPS stands at -0.01 and negative net income per share. Technical indicators are mixed but short-term bullish given price momentum above moving averages. Meyka AI rates the stock 'Hold' with a B grade, forecasting gradual price appreciation over 7 years. Key risks involve thin free cash flow and leverage amid competitive healthcare device sector pressures.
Go toTop